Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sartorius

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Sartorius. Displaying page 1 of 1.
    EudraCT Number: 2016-002714-45 Sponsor Protocol Number: FJD-MET-2016-01 Start Date*: 2017-01-13
    Sponsor Name:Instituto de Investigación Sanitaria Fundación Jiménez Díaz
    Full Title: "Pilot study to assess the efficacy of treatment with metformin in patients with Hidradenitis suppurativa refractory to standard treatment "
    Medical condition: Hidradenitis suppurativa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000042-34 Sponsor Protocol Number: C20-109-07 Start Date*: 2020-09-24
    Sponsor Name:
    Full Title: PROOF OF CONCEPT STUDY ON LTX-109 AS TREATMENT FOR HIDRADENITIS SUPPURATIVA
    Medical condition: Hidradenitis suppurativa, Hurley stage I-III
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2018-000827-15 Sponsor Protocol Number: INCB54707-203 Start Date*: 2018-11-06
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002321-20 Sponsor Protocol Number: HIDRA04 Start Date*: 2015-09-01
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF MABp1, A HUMAN ANTIBODY TARGETING INTERLEUKIN-1ALPHA, IN PATIENTS WITH HIDRADENITIS SUPPURATIVA
    Medical condition: HIDRADENITIS SUPPURATIVA/ACNE INVERSA
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004501-40 Sponsor Protocol Number: IFX-1-P2.4 Start Date*: 2018-07-16
    Sponsor Name:InflaRx GmbH
    Full Title: A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa
    Medical condition: Hidradenitis suppurativa (HS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) BG (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-003400-20 Sponsor Protocol Number: M11-313 Start Date*: 2012-04-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000435-13 Sponsor Protocol Number: JWGKDVAAP0117 Start Date*: 2017-11-13
    Sponsor Name:University Hospital Frankfurt for its Dermatology Department, Clinical Research
    Full Title: Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatmen...
    Medical condition: Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003406-24 Sponsor Protocol Number: M11-810 Start Date*: 2012-03-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Hidradenitis Supperativa
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002988-33 Sponsor Protocol Number: IFX-1-P2.3 Start Date*: 2016-11-04
    Sponsor Name:InflaRx GmbH
    Full Title: An open label Phase II trial to evaluate the safety of IFX-1 in patients with moderate to severe Hidradenitis suppurativa
    Medical condition: Hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003562-20 Sponsor Protocol Number: 2018-018 Start Date*: 2023-03-07
    Sponsor Name:INSTITUT PASTEUR
    Full Title: A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients versus Tetracycline Derivative
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:34:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA